The U.S. Food and Drug Administration (FDA) approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. FDA notes: Genvoya is approved for use in HIV-infected adults and children ages 12 […]

Go to Original Post